About

Dr. Abhishek Kumar is an Associate Professor of Radiology and the Division Chief of Vascular and Interventional Radiology at Rutgers New Jersey Medical School. He is dual board certified in Diagnostic and Interventional Radiology and leads the state's largest clinical and teaching Interventional Radiology practice. His clinical interests include Interventional Oncology, minimally invasive treatments for peripheral arterial disease and critical limb ischemia, endovascular treatment of venous thromboembolic disease, and complex retrieval of IVC filters. Dr. Kumar developed the Y90 radioembolization program at University Hospital in 2017, which has grown to be the highest volume program in New Jersey, and he is nationally recognized for performing Y90 radioembolization, teaching physicians across the country through seminars, conferences, and proctoring. He actively participates in professional societies, serving on committees and as Vice Chair of the Society of Interventional Radiology Early Career Section, and is frequently invited to lecture at national and international radiology conferences. Dr. Kumar is also dedicated to mentorship, serving as faculty advisor to the Interventional Radiology Interest Group at Rutgers NJMS and as course director for the New Jersey Interventional Radiology Symposium.

Research topics

• Surgery
• Internal medicine
• Medicine
• Radiology

Selected publications

• WAAS-based stability analysis and identification of elite palmarosa (Cymbopogon martinii [Roxb.] Wats. var. motia Burk.) lines using multi-trait genotype-ideotype distance index for higher biomass and essential oil in the North-Western Himalayas

  Journal of Applied Research on Medicinal and Aromatic Plants · 2025-01-09

  article
  PublisherDOI

• Development and performance evaluation of green aluminium metal matrix composites reinforced with graphene nanopowder and marble dust

  Nanotechnology Reviews · 2025-01-01

  articleOpen access

  Abstract Sustainable and high-performance composites have gained sufficient attention in recent years. In this regard, an attempt is made to develop aluminium metal matrix composites reinforced with graphene nanopowder and marble dust using the stir casting technique. Marble dust powder was kept constant at 0.5% in all composite samples, while graphene varied between 0.5 and 2.5%. This unique synergic combination of reinforcement shows improvement in the mechanical and tribological properties of composites. The optimum properties of the composites are recorded at 0.5% marble dust and 2% graphene nanopowder-reinforced samples. A maximum drop of 41% in wear rate was observed at 60 N loading conditions at a 0.63 m/s speed within a range of 20–100 N loading and 0.63 and 1.89 m/s rotational speed conditions. The specific wear rate also shows the same trend. The coefficient of friction values also decreased in the composite samples compared to the as-cast aluminium alloy. Toughness values decreased sharply in composite samples; however, a slight increase was observed as reinforcement increased, reaching 9J in the 0.5% marble dust and 2% graphene samples, which was 25% lower than the as-cast alloy sample. Microhardness is improved by 56.9% and tensile strength by 32.5% in the 0.5% marble dust and 2% graphene-reinforced sample, and elongation decreased by 33.7% in the 2.5 % graphene-reinforced sample. SEM characterization of fractured tensile and toughness samples reveals the nature of the failure of composites. SEM of the wear surface shows the wear behaviour of the composites. The overall findings demonstrate that the marble dust and graphene powder hybrid reinforcement offer an optimal balance between the mechanical and tribological properties along with sustainability, paving the way for next-generation green metal matrix composites.

  PublisherOA PDFDOI

• Abstract No. 163 Evaluating the Influence of Socioeconomic Factors, Race, and Obesity on In-Hospital-Mortality and Length of Stay Following Mechanical Thrombectomy for Acute Pulmonary Embolism

  Journal of Vascular and Interventional Radiology · 2025-02-19

  articleOpen access
  PublisherOA PDFDOI

• Author Index

  2024-03-15

  paratextOpen access
  PublisherOA PDFDOI

• Y90 Radiation Segmentectomy versus Microwave Ablation for Hepatocellular Carcinoma in Locations Suboptimal for Percutaneous Ablation

  The Arab Journal of Interventional Radiology · 2024-08-06

  articleOpen accessSenior author

  Purpose The purpose of our study was to evaluate outcomes following percutaneous microwave ablation (MWA) versus yttrium-90 (Y90) radiation segmentectomy (RS) for tumors in suboptimal locations for ablation. Materials and Methods Retrospective review (January 2014-July 2019) was performed on patients who underwent Y90-RS or MWA (with or without prior transarterial chemoembolization [TACE]) with curative intent for early-stage hepatocellular carcinoma (HCC) lesions in suboptimal locations for percutaneous ablation, defined as locations in which needle placement iswithin 5mmof critical structures (liverdome, liver capsule, gallbladder, and hilum). The primary endpoints were treatment response as per themodified Response Evaluation Criteria in Solid Tumors criteria and complications. Statistical Analysis Fischer’s exact test was performed for categorical variables, and Student’s t-tests for nominal variables. Results Twenty-three lesions in 20 patients (13 male, 67±8.8 years) and 30 lesions in 30 patients (18 male, 62.5±10.6 years) were treated with Y90-RS and MWA (19 with prior TACE), respectively. There were no differences in demographics ( p >0.05). Mean tumor diameter was 2.9±1.0 in those treated with Y90-RS and 2.3±0.9 for MWA ( p <0.05). Lesions were located adjacent to the following structures: dome ( n =22), capsule ( n =16), hilum ( n =9), and gallbladder ( n =6). All patients were Eastern Cooperative Oncology Group performance status 0 to 1. Of the MWA cohort, 19 were Child-Pugh class A, 5 were B, and 6 were C and themean pretreatment laboratory values were as follows: Model for End-stage Liver Disease sodium(MELD-Na) 12.7±4.6, alpha-fetoprotein (AFP) 848±3168.0, aspartate aminotransferase (AST) 71.9±49.1, alanine aminotransferase (ALT) 48.0±32.4, and total bilirubin 2.4±2.7. Of the Y90-RS cohort, 15 were Child-Pugh class A, 4 were B, and 1 was C and pretreatment laboratory values were as follows: MELD-Na 10.5±3.3 (Y90-RS), AFP 762.2±1793.8 (Y90), AST 50.3±30.5 (Y90), ALT 30.1±16.9 (Y90), and total bilirubin 1.6±1.1 (Y90). Complete response rate following Y90 was 96 versus 76% for MWA, with no disease progression after Y90-RS within the follow-up period. Three (13%) lesions demonstrated progression of disease (time to progression 6.3 months) after MWA. No grade>2 toxicities or procedure-related complications were noted following Y90-RS. There were 7 major (arterioportal fistula with hemoperitoneum, pneumothorax, liver infarction, and capsular burn) and 3 minor complications following MWA. Conclusion Y90-RS is a valuable alternative to percutaneous MWA as a first-line therapy for early-stage HCC for tumors in suboptimal locations for ablation, offering a favorable treatment response and safety profile.

  PublisherOA PDFDOI

• 1176 Osteomyelitis as a Rare Complication of Delayed Diagnosis Spontaneous Bladder Perforation Post-Pelvic Radiotherapy: A Case Report

  British journal of surgery · 2024-07-01

  articleOpen accessSenior author

  Abstract Spontaneous, delayed bladder perforation is a rare and serious complication of pelvic radiotherapy. Due to its rarity and late presentation, it usually causes further complications which warrant long inpatient stays before a diagnosis is made. Whilst most published cases highlight peritonitis as a common complication, our case has presented differently with pelvic osteomyelitis as another potential complication. Therefore, our objectives are to increase awareness about this presentation and highlight key aspects of quick diagnosis and management to prevent further complications. A 76-year-old gentleman, with background of Parkinson’s disease and pelvic radiotherapy for prostate cancer 11 years ago, presented with gradual onset suprapubic pain. He was managed initially with antibiotics and long-term urethral catheter for pelvic osteomyelitis secondary to urinary bladder perforation and then discharged. However, he was readmitted two weeks later with worsening osteomyelitis, delirium and sub-therapeutic Parkinson’s disease. Therefore, bilateral nephrostomies were inserted for acute kidney injury (AKI), further antibiotics given via a peripheral central catheter (PICC) and a prolonged recovery ensued. The clinical complications of delayed diagnosis of spontaneous bladder perforation in patients with history of pelvic radiotherapy are rare but difficult to manage. In addition, our case is the first one that highlights osteomyelitis as another potential complication and whilst there are different treatment modalities, the decision should be individualised.

  PublisherOA PDFDOI

• TCT-423 Biodegradable-Polymer Coated Sirolimus-Eluting Stents in Diabetic Patients: Insights From the S-FLEX UK II Registry

  Journal of the American College of Cardiology · 2024-10-01 · 1 citations

  article1st authorCorresponding
  PublisherDOI

• Safety and performance of the ultrathin sirolimus-eluting coronary stent in an all-comer patient population: the S-FLEX UK-II registry

  BMJ Open · 2024-10-01 · 1 citations

  articleOpen access

  OBJECTIVE: We evaluated the clinical safety and performance of the ultrathin strut biodegradable polymer-coated Supraflex Cruz (Sahajanand Medical TechnologiesLtd., Surat, India) sirolimus-eluting stent (SES) in an all-comer patient population requiring coronary stent implantation. STUDY DESIGN: The study was a prospective, observational, multicentre, single-arm registry. STUDY SETTINGS: The study was conducted at 19 NHS Hospitals across the UK, from March 2020 to September 2021. STUDY PARTICIPANTS: A total of 1904 patients with symptomatic coronary artery disease (age ≥18 years) who underwent percutaneous coronary intervention with at least one Supraflex Cruz SES were enrolled. PRIMARY AND SECONDARY OUTCOMES MEASURE: The primary endpoint was target lesion failure (TLF), a composite of cardiac death, target vessel myocardial infarction (TV-MI) and clinically indicated target lesion revascularisation (CI-TLR), at 12 months. Safety endpoints were stent thrombosis, all-cause death and any MI. Prespecified subgroups analysis included patients with diabetes mellitus, bifurcation lesion, type B2/C lesion defined as per ACC/AHA (American College of Cardiology/American Heart Association) lesion classification and long coronary lesions (>20 mm). RESULTS: A total of 2973 Supraflex Cruz SES were implanted in 1835 patients (mean age: 65.20±11.03 years). Of these, 404 patients had diabetes mellitus (491 lesions), 271 had bifurcation lesions (293 lesions), 1541 had type B2/C lesions (1832 lesions) and 985 had long coronary lesions (>20 mm, 1139 lesions). Among the overall population, device success was achieved in 98.2% of lesions. TLF occurred in 12 (0.7%) patients (0.3% cardiac death, 0.2% TV-MI, 0.2% CI-TLR) at 30 days and in 43 (2.3%) patients (0.8% cardiac death, 0.8% TV-MI, 0.8% CI-TLR) at 12 months follow-up. The rate of definite stent thrombosis was 0.3% in the overall population at 12 months. The incidence of TLF and stent thrombosis was 6.2% and 1% in the diabetic, 1.8% and none in bifurcation lesion, 2.5% and 0.3% in type B2/C lesion, and 2.7% and 0.3% in long coronary lesions (>20 mm) subgroups, respectively. at 12 months follow-up. CONCLUSION: The S-FLEX UK-II registry confirms the clinical safety and performance of the ultrathin Supraflex Cruz SES in an all-comer population with complex coronary artery disease, demonstrating low rates of TLF and stent thrombosis. TRIAL REGISTRATION NUMBER: ISRCTN39751665 (https://doi.org/10.1186/ISRCTN39751665).

  PublisherOA PDFDOI

• Abstract No. 165 Academic Productivity and NIH Grant Funding in Interventional Radiology

  Journal of Vascular and Interventional Radiology · 2024-02-21

  articleOpen access
  PublisherOA PDFDOI

• TCT-522 Ultrathin Strut Biodegradable Polymer-Coated Sirolimus-Eluting Stents in an All-Comers Patient Population: The Prospective S-FLEX UK-II Registry

  Journal of the American College of Cardiology · 2023-10-01 · 1 citations

  article
  PublisherDOI

Frequent coauthors

• Pratik A. Shukla

  Rutgers, The State University of New Jersey

  173 shared

• Sohail Contractor

  University of Louisville

  54 shared

• Vishnu Chandra

  University of Virginia

  48 shared

• S. Shanmugasundaram

  SRM Dental College

  48 shared

• Antony Sare

  Yale University

  48 shared

• John A. Cieslak

  31 shared

• M. Kolber

  The University of Texas Southwestern Medical Center

  26 shared

• Ethan Wajswol

  Icahn School of Medicine at Mount Sinai

  26 shared

Education

• M.D.

  Texas Tech School of Medicine

  2009

• B.S.

  The University of Texas at Austin

  2005